MedTrace Logo

N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

NCT03746860 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1508

Last updated 2021-05-17

No results posted yet for this study

Summary

Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.

Conditions

  • Allergic Rhinitis Due to House Dust Mite
  • Allergic Asthma Due to Dermatophagoides Farinae
  • Allergic Asthma Due to Dermatophagoides Pteronyssinus

Interventions

DRUG

Tablet, Dispersible

1 tablet/day with 12 SQ-HDM per lyo-tablet

Sponsors & Collaborators

  • ITEC Services

    collaborator OTHER

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Pascal DEMOLY, Pr · Hôpital Arnaud de Villeneuve - 34090 Montpellier - FRANCE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-09
Primary Completion
2020-09-29
Completion
2020-09-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746860 on ClinicalTrials.gov